Skip to main content
. 2020 Nov;12(11):7011–7023. doi: 10.21037/jtd-2019-cptn-07

Figure 3.

Figure 3

Results from the PEMBRO-RT trial (48). Overall survival (A), Progression-free survival (B), and objective response rate (C) for pembrolizumab (pembro) vs. stereotactic body radiation therapy + pembrolizumab (SBRT + pembro). Mo, months; No, number; TPS, tumor proportion score; SBRT, stereotactic body radiation therapy.